A new study published in Lancet reveals that an experimental vaccine manufactured by Merck using a genetically modified adenovirus actually increased the risk of contracting HIV infection in recipients.
Titled, “Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study,” researchers randomly assigned a total of 801 HIV-1 uninfected, sexually active adults aged 18—35 years from five sites in South Africa to receive either the vaccine (400) or a placebo (401). 216 (27%) received only one injection, 529 (66%) received only two injections, and 56 (7%) received three injections.
The results were reported as follows:
At a median follow-up of 42 months (IQR 31—42), 63 vaccine recipients (16%) had HIV-1 infection compared with 37 placebo recipients (9%; adjusted HR 1·70, 95% CI 1·13—2·55; p=0·01). Risk for HIV-1 infection did not differ according to the number of vaccinations received, sex, circumcision, or adenovirus type 5 (Ad5) serostatus.
Differences in risk behaviour at baseline or during the study, or annualised dropout rate (7·7% [95% CI 6·2—9·5] for vaccine recipients vs 8·8% [7·1—10·7] for placebo recipients; p=0·40) are unlikely explanations for the increased rate of HIV-1 infections seen in vaccine recipients.
In other words, those receiving vaccines had a 70% increased risk [HR 1·70] of contracting HIV versus those receiving the placebo. The researchers concluded:
The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses received, warrants further investigation to understand the biological mechanism. We caution against further use of the Ad5 vector for HIV vaccines.
According to a report about the study by Dr. Mark Thoma, MD:
Since the end of the last century, there have been a number of HIV vaccines developed and tested. Over 30 clinical trials of these vaccines have been done to see if they conferred immunity to HIV to those volunteers who agreed to participate in the trials. To date, none of the trials have shown that any of the vaccines can produce significant immunity in a number of people against infection with HIV.
Now, with the discovery of vaccine-enhanced risk of HIV-1 acquisition, clearly there is a risk that the ‘cure’ offered by HIV vaccines may actually be worse than doing nothing at all. The researchers hypothesized that the genetically engineered adenovirus vector used to deliver HIV antigens into the vaccine receiptient may lead to an expansion of activated Ad5-speicfic T cells thereby increasing the number of HIV-1 target cells.
While a specific mechanism has yet to be identified to explain vaccine-enhanced risk, the study clearly shows that rather than conferring increased immunity the vaccine reduces it. With the recent resurgence of measles, whooping cough, varicella (shingles) in highly immunized populations, research like this speaks to fundamental flaws in the vaccine-centric preventive health model.
Perhaps the focus should return to supporting immunity by decreasing unnecessary harmful chemical and biological exposures, and optimizing dietary support for natural immunity – it worked for millions of years before synthetic immunity via vaccines became the dominant paradigm only a half century ago. Also, cases of HIV clearance using natural products should provide sufficient motivation to conduct trials on natural compounds with proven efficacy in cell, animal and preclinical studies.
This article first appeared at GreenMedInfo. Please visit to access their vast database of articles and the latest information in natural health.